Cargando…

Evaluation of Exposure Doses of Elective Nodal Irradiation in Chemoradiotherapy for Advanced Esophageal Cancer

SIMPLE SUMMARY: Surgery has shown that early-stage esophageal cancer is accompanied by extensive lymph node metastasis. Therefore, elective nodal irradiation is indispensable for chemoradiotherapy instead of surgery for the radical cure of esophageal cancer. In contrast, attention must be paid to ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamamura, Hiroyasu, Hasatani, Kenkei, Matsumoto, Sae, Asahi, Satoko, Tatebe, Hitoshi, Sato, Yoshitaka, Matsusita, Keiichiro, Tameshige, Yuji, Maeda, Yoshikazu, Sasaki, Makoto, Takamatsu, Shigeyuki, Yamamoto, Kazutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913169/
https://www.ncbi.nlm.nih.gov/pubmed/36765818
http://dx.doi.org/10.3390/cancers15030860
_version_ 1784885359853699072
author Tamamura, Hiroyasu
Hasatani, Kenkei
Matsumoto, Sae
Asahi, Satoko
Tatebe, Hitoshi
Sato, Yoshitaka
Matsusita, Keiichiro
Tameshige, Yuji
Maeda, Yoshikazu
Sasaki, Makoto
Takamatsu, Shigeyuki
Yamamoto, Kazutaka
author_facet Tamamura, Hiroyasu
Hasatani, Kenkei
Matsumoto, Sae
Asahi, Satoko
Tatebe, Hitoshi
Sato, Yoshitaka
Matsusita, Keiichiro
Tameshige, Yuji
Maeda, Yoshikazu
Sasaki, Makoto
Takamatsu, Shigeyuki
Yamamoto, Kazutaka
author_sort Tamamura, Hiroyasu
collection PubMed
description SIMPLE SUMMARY: Surgery has shown that early-stage esophageal cancer is accompanied by extensive lymph node metastasis. Therefore, elective nodal irradiation is indispensable for chemoradiotherapy instead of surgery for the radical cure of esophageal cancer. In contrast, attention must be paid to adverse effects when applying radiation to a wide area. Adverse events are generally more intense with high-dose irradiation. Therefore, determining the appropriate dose for prophylactic irradiation to the elective nodal area is important. However, the appropriate dose has not been fixed. In this study, the therapeutic effects and adverse events of a group of 36 Gy elective nodal irradiation doses were similar to those of 40 Gy or higher. This study’s results indicate that preventing lymph node metastasis at lower doses is possible, thus suppressing adverse events. ABSTRACT: We evaluated elective nodal irradiation (ENI) doses during radical chemoradiotherapy (CRT) for esophageal cancer (EC). A total of 79 patients (65 men and 14 women) aged 52–80 years with T1-3, N0-3, and M0 (including M1ly) who underwent CRT for EC during November 2012–September 2019 were eligible for this retrospective analysis. Patients were divided into two groups: the high-dose group (HG), including 38 patients who received ≥40 Gy as ENI; and the low-dose group (LG), including 41 patients who received <40 Gy. The median doses were 40.0 and 36.0 Gy in HG and LG, respectively. During the follow-up (median: 36.7 months), no lymph node recurrence was observed in the ENI field in all patients. Lymph node recurrence near the ENI field was observed in six patients. No significant differences were observed between the two groups in median overall survival, progression-free survival, and local control. Grade 3–4 acute and late adverse events were observed in five patients of HG and six patients of LG, respectively. No ulceration or stricture was observed in the ENI field on endoscopy examined with 58 Gy irradiation. In conclusion, an ENI dose of 36 Gy could be considered to control the elective nodes of EC.
format Online
Article
Text
id pubmed-9913169
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99131692023-02-11 Evaluation of Exposure Doses of Elective Nodal Irradiation in Chemoradiotherapy for Advanced Esophageal Cancer Tamamura, Hiroyasu Hasatani, Kenkei Matsumoto, Sae Asahi, Satoko Tatebe, Hitoshi Sato, Yoshitaka Matsusita, Keiichiro Tameshige, Yuji Maeda, Yoshikazu Sasaki, Makoto Takamatsu, Shigeyuki Yamamoto, Kazutaka Cancers (Basel) Article SIMPLE SUMMARY: Surgery has shown that early-stage esophageal cancer is accompanied by extensive lymph node metastasis. Therefore, elective nodal irradiation is indispensable for chemoradiotherapy instead of surgery for the radical cure of esophageal cancer. In contrast, attention must be paid to adverse effects when applying radiation to a wide area. Adverse events are generally more intense with high-dose irradiation. Therefore, determining the appropriate dose for prophylactic irradiation to the elective nodal area is important. However, the appropriate dose has not been fixed. In this study, the therapeutic effects and adverse events of a group of 36 Gy elective nodal irradiation doses were similar to those of 40 Gy or higher. This study’s results indicate that preventing lymph node metastasis at lower doses is possible, thus suppressing adverse events. ABSTRACT: We evaluated elective nodal irradiation (ENI) doses during radical chemoradiotherapy (CRT) for esophageal cancer (EC). A total of 79 patients (65 men and 14 women) aged 52–80 years with T1-3, N0-3, and M0 (including M1ly) who underwent CRT for EC during November 2012–September 2019 were eligible for this retrospective analysis. Patients were divided into two groups: the high-dose group (HG), including 38 patients who received ≥40 Gy as ENI; and the low-dose group (LG), including 41 patients who received <40 Gy. The median doses were 40.0 and 36.0 Gy in HG and LG, respectively. During the follow-up (median: 36.7 months), no lymph node recurrence was observed in the ENI field in all patients. Lymph node recurrence near the ENI field was observed in six patients. No significant differences were observed between the two groups in median overall survival, progression-free survival, and local control. Grade 3–4 acute and late adverse events were observed in five patients of HG and six patients of LG, respectively. No ulceration or stricture was observed in the ENI field on endoscopy examined with 58 Gy irradiation. In conclusion, an ENI dose of 36 Gy could be considered to control the elective nodes of EC. MDPI 2023-01-30 /pmc/articles/PMC9913169/ /pubmed/36765818 http://dx.doi.org/10.3390/cancers15030860 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tamamura, Hiroyasu
Hasatani, Kenkei
Matsumoto, Sae
Asahi, Satoko
Tatebe, Hitoshi
Sato, Yoshitaka
Matsusita, Keiichiro
Tameshige, Yuji
Maeda, Yoshikazu
Sasaki, Makoto
Takamatsu, Shigeyuki
Yamamoto, Kazutaka
Evaluation of Exposure Doses of Elective Nodal Irradiation in Chemoradiotherapy for Advanced Esophageal Cancer
title Evaluation of Exposure Doses of Elective Nodal Irradiation in Chemoradiotherapy for Advanced Esophageal Cancer
title_full Evaluation of Exposure Doses of Elective Nodal Irradiation in Chemoradiotherapy for Advanced Esophageal Cancer
title_fullStr Evaluation of Exposure Doses of Elective Nodal Irradiation in Chemoradiotherapy for Advanced Esophageal Cancer
title_full_unstemmed Evaluation of Exposure Doses of Elective Nodal Irradiation in Chemoradiotherapy for Advanced Esophageal Cancer
title_short Evaluation of Exposure Doses of Elective Nodal Irradiation in Chemoradiotherapy for Advanced Esophageal Cancer
title_sort evaluation of exposure doses of elective nodal irradiation in chemoradiotherapy for advanced esophageal cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913169/
https://www.ncbi.nlm.nih.gov/pubmed/36765818
http://dx.doi.org/10.3390/cancers15030860
work_keys_str_mv AT tamamurahiroyasu evaluationofexposuredosesofelectivenodalirradiationinchemoradiotherapyforadvancedesophagealcancer
AT hasatanikenkei evaluationofexposuredosesofelectivenodalirradiationinchemoradiotherapyforadvancedesophagealcancer
AT matsumotosae evaluationofexposuredosesofelectivenodalirradiationinchemoradiotherapyforadvancedesophagealcancer
AT asahisatoko evaluationofexposuredosesofelectivenodalirradiationinchemoradiotherapyforadvancedesophagealcancer
AT tatebehitoshi evaluationofexposuredosesofelectivenodalirradiationinchemoradiotherapyforadvancedesophagealcancer
AT satoyoshitaka evaluationofexposuredosesofelectivenodalirradiationinchemoradiotherapyforadvancedesophagealcancer
AT matsusitakeiichiro evaluationofexposuredosesofelectivenodalirradiationinchemoradiotherapyforadvancedesophagealcancer
AT tameshigeyuji evaluationofexposuredosesofelectivenodalirradiationinchemoradiotherapyforadvancedesophagealcancer
AT maedayoshikazu evaluationofexposuredosesofelectivenodalirradiationinchemoradiotherapyforadvancedesophagealcancer
AT sasakimakoto evaluationofexposuredosesofelectivenodalirradiationinchemoradiotherapyforadvancedesophagealcancer
AT takamatsushigeyuki evaluationofexposuredosesofelectivenodalirradiationinchemoradiotherapyforadvancedesophagealcancer
AT yamamotokazutaka evaluationofexposuredosesofelectivenodalirradiationinchemoradiotherapyforadvancedesophagealcancer